Baylor Neurosurgery named GammaTile Center of Excellence

Baylor St. Luke's Medical Center has been designated as the latest GammaTile® Center of Excellence Program by GT Medical Technologies, a medical device company dedicated to improving the lives of patients with brain tumors.

The program recognizes leaders in patient care dedicated to advancing brain tumor treatment. Physicians and their institutions who receive this designation have demonstrated an exceptional level of expertise in the GammaTile procedure by meeting specific clinical criteria, annual case minimums, and ongoing education requirements.

The following physicians are now recognized with achievement:

• Ganesh Rao, MD, Neurosurgeon
• Akash Patel, MD, Neurosurgeon
• Ali Jalali, MD, PhD, Neurosurgeon
• Snehal Desai, MD, Radiation Oncologist
• Zaid Siddiqui, MD, Radiation Oncologist
• Daniel Hamstra, MD, PhD, Radiation Oncologis

"Achieving designation as a GammaTile Center of Excellence highlights our team's dedication to bringing innovative treatment options to patients with operable brain tumors," said Dr. Ganesh Rao, Physician Lead for the Neuroscience Service Line at Baylor St. Luke's Medical Center and Professor and Marc J. Shapiro Chair of Neurosurgery at Baylor College of Medicine. "With GammaTile, we can deliver targeted radiation precisely where it is needed at the time of surgery, minimizing exposure to healthy tissue. At Baylor St. Luke's Medical Center, we believe that GammaTile is an important advancement in brain tumor care that strengthens our ability to provide the best treatment available to our patients."

GammaTile is an innovative form of radiation therapy placed at the time of tumor removal surgery, delivering immediate, targeted radiation to the tumor site when cancer cells are at their lowest levels. Unlike conventional approaches, which often require a delay between surgery and radiation therapy to allow for wound healing, GammaTile eliminates this treatment gap. By delivering immediate, localized radiation directly at the tumor site, it is designed to maximize the treatment's effectiveness against remaining cancer cells and reduce the risk of regrowth.